Small Molecule
UNC
University of North Carolina (UNC) is exploring an investigational Small Molecule Paternal Activation approach to treating Angelman syndrome.
University of North Carolina (UNC) is exploring an investigational Small Molecule Paternal Activation approach to treating Angelman syndrome.
This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.
A low molecular weight compound that is small enough to easily get into tissues, enter cells, and interact with specific biological targets. In AS, small molecules could be developed that function as drugs by modulating biochemical pathways, inhibiting or activating specific proteins, or altering cellular processes shown to be altered in AS neurons. These targets of small molecules can be proteins, DNA, RNA or the ATS.
Researchers identify potential treatment for Angelman syndrome